NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
Pablo Corral/LinkedIn
Nov 10, 2025, 10:16

Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:

”Breaking from AHA25

The phase 3 CORALreef HeFH trial brings a major step forward: the first oral PCSK9 inhibitor, enlicitide, cuts LDL-C by ≈60% vs placebo in adults with heterozygous familial hypercholesterolemia already on maximally tolerated statins.

  1. LDL-C ↓58% at 24 weeks and sustained −55% at 52 weeks
  2. ApoB ↓48%, non-HDL-C ↓52%, Lp(a) ↓25%
  3. >70% reached LDL < 70 mg/dL, with excellent tolerability
  4. No excess in adverse events vs placebo

Enlicitide (oral PCSK9 inhibitor, 20 mg QD) shows efficacy comparable to injectable antibodies — potentially transforming lipid management for HeFH and beyond. doi:10.1001/jama.2025.20620”

Read the full article here.

Article: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia

Authors: Christie M. Ballantyne, Laura Gellis, Jean-Claude Tardif, Puja Banka, Ann Marie Navar, Emil Andreas Asprusten, Russell Scott, Erik S. G. Stroes, Samar Froman, Geraldine Mendizabal, Fan Wang, Alberico L. Catapano

Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward

Stay updated on all scientific advances with Hemostasis Today.

AHA25 Alberico L Catapano Ann Marie Navar Christie M. Ballantyne CORALreef HeFH Emil Andreas Asprusten enlicitide Erik S. G. Stroes Fan Wang Geraldine Mendizabal Health HeFH Hematology Hemostasis Hemostasis Today JAMA Jean-Claude Tardif Laura Gellis LDL Medicine Pablo Corral PCSK9 inhibitor Puja Banka Russell Scott Samar Froman statins thrombosis
NewsFeed